Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 10/20 | 0.42 |
| ▸ | HRH1 | P35367 | 10/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093537 | 0.91 | KCNA5 (0.49) | KCNA5HRH2HRH1HRH3ALDH1A1 | |
| SCHEMBL2967821 | 0.88 | KCNH2 (0.48) | KCNA5KDM4EHRH2HRH1HRH3 | |
| SCHEMBL5965670 | 0.83 | KCNA5 (0.44) | KCNA5HRH2HRH1HRH3ALDH1A1 | |
| SCHEMBL7035960 | 0.83 | KCNH2 (0.49) | KDM4ESMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL2964375 | 0.83 | KCNH2 (0.54) | HRH2HRH1HRH3 | |
| SCHEMBL6622255 | 0.83 | GPR119 (0.49) | KCNA5HRH2HRH1HRH3 | |
| SCHEMBL6995039 | 0.82 | GRIN1 (0.42) | KDM4EHRH3ALDH1A1MAPT | |
| SCHEMBL6995238 | 0.81 | HTR1A (0.40) | HRH2HRH1HRH3 | |
| SCHEMBL6986200 | 0.80 | CCR3 (0.39) | KCNA5HRH2HRH1 | |
| SCHEMBL7033675 | 0.80 | HRH2 (0.37) | HRH2HRH1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | KCNH1, LBR, CACNA1E | KCNA5 79/4885KDM4E 4058/4885SMN1; SMN2 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.